Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA accepts for review BioMimetic's PMA for Augment bone graft

July 2, 2010

New glucagon receptor antagonist DSR-17759 shows antidiabetic promise in preclinical evaluation

July 2, 2010

DPP-IV inhibitor LC15-0444 safe and improves glycemic control in Korean type 2 diabetes patients

July 2, 2010

Alnylam obtains approval to initiate phase I ALN-TTR01 study in amyloidosis

July 1, 2010

Tolerx begins confirmatory phase III trial of otelixizumab in type 1 diabetes

July 1, 2010

Vitae receives milestone payment as 11-beta-HSD1 inhibitor advances to phase I

July 1, 2010

FDA grants orphan drug status to Octreolin for oral treatment of acromegaly

July 1, 2010

Solvay discloses new potassium channel blockers

July 1, 2010

Raptor begins enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

June 30, 2010

Palatin Technologies claims new melanocortin receptor ligands

June 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...